Showing 5261-5270 of 9243 results for "".
Meeting the Needs of Today's Injectables Market
https://practicaldermatology.com/videos/c-suite-chats/meeting-needs-todays-injectables-market/26926/David Moatazedi, president and CEO of Evolus, talks about trends in the injectables market and the needs of younger generations.Innovations in the Aesthetic Market and Wrinkle Removal Technology
https://practicaldermatology.com/series/c-suite-chats/innovations-aesthetic-market-and-wrinkle-removal-technology/26732/Lou Scafuri, CEO of SofWave Medical, talks about what makes the company’s Synchronous Ultrasound Parallel Beam technology unique.PASI-HD: New Method for Measuring Severity in Mild to Moderate Plaque Psoriasis
https://practicaldermatology.com/topics/psoriasis/pasi-hd-new-method-for-measuring-severity-in-mild-to-moderate-plaque-psoriasis/20185/Robert Higham, MPAS, PA-C, Executive Director of Clinical Development of Arcutis Biotherapeutics, discusses PASI-HD, a new measure designed to assess severity and therapeutic response in patients with mild and moderate psoriasis. PASI High Discrimination (PASI-HD) was developed to better understandMeaningful Innovation in Medical Dermatology at Arcutis Biotherapeutics
https://practicaldermatology.com/topics/psoriasis/meaningful-innovation-in-medical-dermatology-at-arcutis-biotherapeutics/20099/Frank Watanabe, President and CEO of Arcutis Biotherapeutics, shares what “meaningful innovation” means to Arcutis and how the company aims to create meaningful change for people living with chronic skin conditions.Scientifically Speaking: New Directions in Acne Management, Part 1
https://practicaldermatology.com/videos/scientifically-speaking/scientifically-speaking-new-directions-in-acne-management-part-1/19939/The recognition that inflammation is at the heart of acne has led to changes in management approaches and better understanding of how treatments work. In the first of a 2-part series, host Joel L. Cohen, MD talks to Diane Berson, MD; Linda Stein Gold, MD; and Emil Tanghetti, MD about acne approachesDoes Diet Matter in Management of Psoriasis?
https://practicaldermatology.com/topics/psoriasis/does-diet-matter-in-management-of-psoriasis/19653/Ronald Prussick, MD says there are dietary changes patients with psoriasis can make to potentially help manage their disease and lower their BMI, which can help improve psoriasis symptoms. He shares some tips and discusses when a referral to a registered dietician makes sense.PsO Treatment Guidelines: The Role of Systemic Medications
https://practicaldermatology.com/topics/psoriasis/pso-treatment-guidelines-the-role-of-systemic-medications/19649/Biologics and new JAK inhibitors play an important role in managing psoriasis. Neal Bhatia, MD offers his thoughts on when and why these treatments should be considered.What people want and why it matters
https://practicaldermatology.com/topics/general-topics/what-people-want-and-why-it-matters/19526/Our patients differ in both their skin biology and their use of skin care products on a daily basis. Discover how understanding the behaviors and practices of men and women can allow better and more effective product recommendations.Avoid the Three Most Common Asset Protection Mistakes
https://practicaldermatology.com/topics/practice-management/avoid-the-three-most-common-asset-protection-mistakes/18368/OJM Group principal David Mandell, JD, MBA discusses the importance of protecting personal and business assets from lawsuits, and outlines strategies to avoid the three asset protection mistakes made by most doctors. Click here to request or download a free copy of Wealth Protection Planning for DeRhatigan to Merz, MOC Dissatisfaction, Syneron-Candela Sale
https://practicaldermatology.com/videos/dermwire-tv/dermwiretv-rhatigan-to-merz-moc-dissatisfaction-syneron-candela-sale/18485/Industry veteran Bob Rhatigan is the new President and Chief Executive Officer of Merz North America. Patrick Urban is new Chief Commercial Officer. In a transaction valued at approximately $397 million, an affiliate of funds advised by Apax Partners will acquire all of the outstanding shares of Sy